DrugPatentWatch Database Preview
Acadia Pharms Inc Company Profile
What is the competitive landscape for ACADIA PHARMS INC, and when can generic versions of ACADIA PHARMS INC drugs launch?
There are fourteen US patents protecting ACADIA PHARMS INC drugs.
There are one hundred and thirty patent family members on ACADIA PHARMS INC drugs in twenty-seven countries.
Summary for Acadia Pharms Inc
| International Patents: | 130 |
| US Patents: | 14 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Acadia Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-001 | Apr 29, 2016 | RX | Yes | Yes | 7,732,615 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-001 | Apr 29, 2016 | RX | Yes | Yes | 8,618,130 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-001 | Apr 29, 2016 | RX | Yes | Yes | 9,296,694 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-001 | Apr 29, 2016 | RX | Yes | Yes | 7,858,789 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Acadia Pharms Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,008,323 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | ➤ Try a Free Trial |
| 7,393,861 | Derivatives of 4-aminopiperidine and their use as a medicament | ➤ Try a Free Trial |
| 2,017,165,273 | ➤ Try a Free Trial | |
| 7,994,193 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Acadia Pharms Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2266282 | ➤ Try a Free Trial |
| Cyprus | 1108642 | ➤ Try a Free Trial |
| Denmark | 1587789 | ➤ Try a Free Trial |
| Portugal | 1587789 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
